Cor Vasa 2022, 64(1):61-65 | DOI: 10.33678/cor.2021.141

(Pharmacotherapy of chronic heart failure from the viewpoint of the new ESC 2021 guidelines)

Jaroslav Brotánek
Interní klinika, 3. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, 1. lékařská fakulta Univerzity Karlovy, Praha

Chronic heart failure is a disease exhibiting high mortality and morbidity and leading to a significant deterioration in the patients' quality of life. Our treatment of patients suffering from this disease aims to improve their clinical condition while reducing their mortality and frequency of hospitalizations for heart failure. In recent years a considerable progress has been made in the treatment of patients with chronic heart failure, which has led to improvements in the above factors. This article offers a brief summary of the pharmacotherapy of chronic heart failure as it was published in the new 2021 guidelines of the European Society of Cardiology.

Keywords: ACE inhibitors

Received: December 13, 2021; Accepted: December 15, 2021; Published: February 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. (Pharmacotherapy of chronic heart failure from the viewpoint of the new ESC 2021 guidelines). Cor Vasa. 2022;64(1):61-65. doi: 10.33678/cor.2021.141.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018;391:572-580. Go to original source... Go to PubMed...
    2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789-1858. Go to original source... Go to PubMed...
    3. van Riet EE, Hooes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016;18:242-252. Go to original source... Go to PubMed...
    4. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996-1004. Go to original source... Go to PubMed...
    5. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 2018;6:678-685. Go to original source... Go to PubMed...
    6. Shah RU, Klein L, Lloyd-Jones DM. Heart failure in women: epidemiology, biology and treatment. Womens Health (Lond) 2009;5:517-527. Go to original source... Go to PubMed...
    7. Motiejunaite J, Akiyama E, Cohen-Solal A, et al. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. Eur Heart J 2020;41:1357-1364. Go to original source... Go to PubMed...
    8. Barasa A, Schaufelberger M, Lappas G, et al. Heart failure in young adults: 20-year trends in hospitalisation, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25-32. Go to original source... Go to PubMed...
    9. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    10. Packer M, Anker SD, Butler J. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424. Go to original source... Go to PubMed...
    11. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146. Go to original source... Go to PubMed...
    12. Gayat E, Arrigo M, Littnerova S, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart Fail 2018;20:345-354. Go to original source... Go to PubMed...
    13. The CONSENSUS Trial Study Group. Enalapril for congestive heart failure. N Engl J Med 1987;317:1349-1351. Go to original source... Go to PubMed...
    14. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group. Circulation 1999;100:2312-2318. Go to original source... Go to PubMed...
    15. Wilson PP, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. Go to original source... Go to PubMed...
    16. CIBIS Investigators and committees. A Randomized Trial of β-Blockade in Heart Failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773. Go to original source... Go to PubMed...
    17. CIBIS-II Investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13. Go to original source...
    18. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426-2435. Go to original source... Go to PubMed...
    19. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469-479. Go to original source... Go to PubMed...
    20. Castagno D, Jhund PS, McMurray JJV, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS II) trial. Eur J Heart Fail 2010;12:607-616. Go to original source... Go to PubMed...
    21. Hossain MA, Ahmed K, Kabir MF, et al. A comparative study of bisoprolol with carvedilol on LV systolic function in patients with chronic heart failure. Univ Heart J 2018;14:3-8. Go to original source...
    22. Wai B, Kearney LG, Hare DL, et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol 2012;11:14. Go to original source... Go to PubMed...
    23. Lábr K, Špinar J, Pařenica J, et al. Betablokátory v registru chronického srdečního selhání FAR NHL. Kardiol Rev Int Med 2017;19(1):68-72.
    24. Málek F. Optimalizace léčby pacientů se srdečním selháním. Med Prom 2020;1:28-31.
    25. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009;150:784-794. Go to original source... Go to PubMed...
    26. Widimský J jr., Widimský J, et al. Hypertenze. Praha: Triton, 2014.
    27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. Go to original source... Go to PubMed...
    28. Vítovec J, Špinar J, Špinarová L. Heart failure and inhibition of renin-angiotensin-aldosteron system. Cor Vasa 2018;60: e263-e273. Go to original source...
    29. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. Go to original source... Go to PubMed...
    30. Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017;5:333-340. Go to original source... Go to PubMed...
    31. Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018;6:489-498. Go to original source... Go to PubMed...
    32. Špinar J, Vítovec J, Špinarová L. SGLT2 (glifloziny) antidiabetika, antihypertenziva nebo léky na srdeční selhání? Kardiol Rev Int Med 2017;19(3):195-200.
    33. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14:782-790. Go to original source... Go to PubMed...
    34. Zinman B, Wanner CH, Lachin JM, et al. The EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128. Go to original source... Go to PubMed...
    35. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. Go to original source... Go to PubMed...
    36. Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424. Go to original source... Go to PubMed...
    37. Faris R, Flather M, Purcell H, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158. Go to original source... Go to PubMed...
    38. Vítovec J, Špinar J, Špinarová L. Moderní trendy ve farmakologické léčbě srdečního selhání. Klin Farmakol Farm 2021;35(2):54-59. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes